Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
Cancer · 15.03.2025 · 131 (S1)
DOI: 10.1002/cncr.35784 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 02.04.2025. Verfasst von Antoine Desilets und 3 weiteren Autor:innen. Beteiligte Einrichtung: Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Lung Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
ROS1 rearrangements define a molecular subset of non–small cell lung cancer (NSCLC) by accounting for 1%–2% of cases. Targeted therapy with ROS1 tyrosine kinase inhibitors (TKIs) has significantly improved the outcomes for these patients. First‐generation inhibitors, such as crizotinib and entrectinib, have demonstrated impressive efficacy, with objective response rates exceeding 60%–70%. However, the emergence of resistance mechanisms, including solvent‐front mutations such as ROS1 G2032R, and limited blood–brain barrier penetration have limited the long‐term efficacy of early‐generation agents. Next‐generation TKIs, including lorlatinib, taletrectinib, and repotrectinib, have been developed to overcome these challenges. These agents show enhanced central nervous system (CNS) penetration and activity against on‐target ROS1 resistance mutations. Repotrectinib, a potent, CNS‐penetrant ROS1 inhibitor, has demonstrated superior activity in both TKI‐naive and ‐resistant tumors, including those harboring the G2032R mutation. Zidesamtinib, a highly selective next‐generation ROS1 inhibitor, further addresses TRK‐mediated off‐target neurological toxicities seen with prior agents, and is poised to offer improved tolerability. Ongoing research is focused on optimizing sequencing strategies for ROS1 inhibitors and exploring combination approaches to prevent or overcome resistance. In addition, the development of novel diagnostic tools, including RNA‐based next‐generation sequencing, has enhanced the detection of functional ROS1 fusions by ensuring that patients with actionable mutations receive appropriate targeted therapies. These advances highlight the evolving landscape of treatment for ROS1 ‐positive NSCLC, with the aim of maximizing long‐term survival and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Diagnostic Molecular Pathology, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Weill Cornell Medicine and New York Presbyterian Hospital, New York, New York, USA.
ORCID-Profile: Alexander Drilon
Förderung
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Desilets, A., Repetto, M., Yang, S. R., & Drilon, A. (2025). Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions. Cancer, 131(S1). https://doi.org/10.1002/cncr.35784
Vancouver
Desilets A, Repetto M, Yang SR, Drilon A. Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions. Cancer. 2025;131(S1). doi:10.1002/cncr.35784
BibTeX
@article{Desilets2025,
author = {Desilets, Antoine and Repetto, Matteo and Yang, Soo-Ryum and Drilon, Alexander},
title = {Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions},
journal = {Cancer},
year = {2025},
volume = {131},
number = {S1},
doi = {10.1002/cncr.35784}
}
EUVIMED